Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 47 · MACD above its signal
None of the 29 investors followed here reported a position in OTSKY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
| Member | Buys | Sells | Est. net | Last move |
|---|---|---|---|---|
| Alan Armstrong Sen. OK | 1 | +$8.0K | Bought Mar 30, 26 |
| Traded | Member | Owner | Type | Amount | Filed | Report |
|---|---|---|---|---|---|---|
| Mar 30, 26 | Alan Armstrong Sen. OK | Self | Buy | $1,001 - $15,000 | Jul 21, 26 (113d) | Report |
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for OTSKY.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.8 | 14.1 | 3.4 | 4.3 | -1.0 | -8.3 | 2.8 | 10.7 | -3.5 | -1.9 | +27.3% | ||
| 2025 | -4.0 | -6.4 | 6.6 | -6.6 | 4.3 | -2.5 | -4.1 | 10.5 | 1.8 | 1.9 | 4.3 | 0.0 | +4.2% |
| 2024 | 4.7 | 3.4 | 2.7 | 2.5 | -3.5 | 3.2 | 20.7 | 16.6 | -5.1 | 7.0 | -4.3 | -6.1 | +45.8% |
| 2023 | -1.6 | -5.9 | 4.8 | 8.2 | 7.8 | -0.9 | 0.0 | 4.0 | -6.3 | -5.2 | 13.6 | -2.9 | +14.5% |
| 2022 | -6.5 | 1.3 | -0.2 | -2.5 | -1.1 | 6.9 | 0.3 | -8.5 | -2.9 | 0.9 | 6.9 | -4.7 | −10.8% |
| 2021 | 0.0 | -6.4 | 5.5 | -9.7 | 9.3 | -0.8 | -4.5 | 7.3 | 0.9 | -8.3 | -8.8 | 1.7 | −14.8% |
| 2020 | -0.6 | -17.2 | 5.4 | 1.2 | 15.2 | -3.6 | -4.8 | 5.7 | -3.7 | -11.9 | 8.7 | 6.2 | −3.8% |
| 2019 | 1.2 | 1.9 | -6.1 | -9.2 | -6.3 | -2.2 | 12.8 | 11.3 | -8.8 | 11.7 | 4.5 | 2.4 | +10.2% |
| 2018 | 1.7 | 12.7 | 0.1 | 4.1 | -4.4 | -3.3 | -4.5 | 1.4 | 7.6 | -5.3 | 0.9 | -16.0 | −7.8% |
| 2017 | 4.7 | -1.0 | -0.3 | 1.7 | -2.0 | -5.5 | 3.3 | -8.9 | -1.3 | 5.5 | 6.2 | -1.3 | 0.0% |
| 2016 | -5.1 | 4.7 | 2.7 | 6.8 | 4.6 | 13.2 | 3.0 | -8.5 | 5.5 | -4.1 | -5.1 | 5.6 | +23.1% |
| 2015 | 2.8 | -2.6 | 4.8 | 1.1 | -1.5 | 2.8 | 11.9 | -5.2 | -6.1 | 4.1 | -0.2 | 7.2 | +19.1% |
| 2014 | 4.5 | 0.9 | -2.1 | -3.9 | -2.1 | 10.0 | 2.1 | 14.0 | -5.5 | 4.3 | -11.5 | -5.3 | +2.4% |
| 2013 | 15.7 | -2.0 | 8.9 | 1.4 | -8.8 | 2.8 | -1.8 | -4.3 | -6.1 | -1.5 | 2.5 | -0.3 | +4.3% |
| 2012 | -2.7 | -0.1 | -2.1 | -5.0 | −9.5% |
Buy / hold / sell counts
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.